Unicycive Therapeutics, Inc. (UNCY) – What Are Researchers Saying About This Stock?

Shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY) have received an average rating of “Moderate Buy” from the seven ratings firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $18.25.

UNCY has been the subject of several recent analyst reports. B. Riley Financial reiterated a “buy” rating and issued a $20.00 target price (down from $22.00) on shares of Unicycive Therapeutics in a research note on Wednesday, August 12th. Guggenheim reissued a “buy” rating and set a $25.00 price target (down from $37.00) on shares of Unicycive Therapeutics in a research report on Thursday, August 13th. Zacks Research upgraded Unicycive Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 19th. Wall Street Zen upgraded Unicycive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Finally, Benchmark reaffirmed a “speculative buy” rating and issued a $15.00 price objective (up from $13.00) on shares of Unicycive Therapeutics in a research report on Thursday, August 20th.

Unicycive Therapeutics Price Performance

Shares of UNCY stock opened at $3.74 on Tuesday. The company has a fifty day moving average price of $4.54 and a two-hundred day moving average price of $6.09. Unicycive Therapeutics has a one year low of $3.35 and a one year high of $8.74. The stock has a market cap of $104.16 million, a P/E ratio of -2.14 and a beta of 1.83.

Unicycive Therapeutics (NASDAQ:UNCY) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.41. As a group, equities research analysts anticipate that Unicycive Therapeutics will post -1.16 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in UNCY. Chicago Partners Investment Group LLC raised its stake in Unicycive Therapeutics by 26.0% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 26,966 shares of the company’s stock valued at $105,000 after acquiring an additional 5,556 shares during the period. Pinnacle Wealth Planning Services Inc. bought a new position in Unicycive Therapeutics during the third quarter worth $36,000. Seven Fleet Capital Management LP boosted its position in Unicycive Therapeutics by 85.6% during the second quarter. Seven Fleet Capital Management LP now owns 103,400 shares of the company’s stock worth $521,000 after purchasing an additional 47,700 shares during the period. Bank of New York Mellon Corp bought a new position in Unicycive Therapeutics during the second quarter worth $248,000. Finally, Bank of America Corp DE increased its holdings in shares of Unicycive Therapeutics by 19,327.6% in the first quarter. Bank of America Corp DE now owns 29,530 shares of the company’s stock valued at $194,000 after purchasing an additional 29,378 shares during the last quarter. 40.42% of the stock is owned by institutional investors and hedge funds.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc (NASDAQ: UNCY) is a clinical-stage biotechnology company focused on developing treatments for kidney disease and related metabolic complications. The company’s primary focus is hyperphosphatemia, an excess of phosphate in the blood that commonly affects people with chronic kidney disease, particularly those receiving dialysis.

Unicycive’s lead product candidate is oxylanthanum carbonate (OLC), an investigational, orally administered phosphate binder designed to bind dietary phosphate in the gastrointestinal tract and reduce its absorption into the bloodstream.